These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21109688)

  • 21. Gene Modified T Cell Therapies for Hematological Malignancies.
    Abramowski-Mock U; Delhove JM; Qasim W
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):913-926. PubMed ID: 28895856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular immunology lessons from therapeutic T-cell receptor gene transfer.
    Thomas S; Stauss HJ; Morris EC
    Immunology; 2010 Feb; 129(2):170-7. PubMed ID: 20561357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing T-cell receptor gene therapy for hematologic malignancies.
    Morris EC; Stauss HJ
    Blood; 2016 Jun; 127(26):3305-11. PubMed ID: 27207802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
    Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
    Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
    van Loenen MM; de Boer R; Hagedoorn RS; Jankipersadsing V; Amir AL; Falkenburg JH; Heemskerk MH
    Gene Ther; 2013 Aug; 20(8):861-7. PubMed ID: 23364317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer.
    Li G; Park K; Davila ML
    Methods Mol Biol; 2017; 1514():111-118. PubMed ID: 27787796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
    Schaft N; Lankiewicz B; Drexhage J; Berrevoets C; Moss DJ; Levitsky V; Bonneville M; Lee SP; McMichael AJ; Gratama JW; Bolhuis RL; Willemsen R; Debets R
    Int Immunol; 2006 Apr; 18(4):591-601. PubMed ID: 16507598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice.
    Schmidt K; Keller C; Kühl AA; Textor A; Seifert U; Blankenstein T; Willimsky G; Kloetzel PM
    Cancer Res; 2018 Jun; 78(12):3243-3254. PubMed ID: 29559473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
    Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
    Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.
    Ivanov R; Hol S; Aarts TI; Hagenbeek A; Ebeling SB
    Clin Exp Immunol; 2006 Jan; 143(1):78-84. PubMed ID: 16367937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies.
    Chen L; Dong L; Ma Y; Wang J; Qiao D; Tian G; Wang M
    BMC Immunol; 2021 Sep; 22(1):65. PubMed ID: 34583647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.